See how the ULSPIRA solution can help reduce your burden of care

Watch the ULSLPIRA Solution Video

Spend more time with your patients and less time managing equipment with the ULSPIRA Solution.

Download the ULSPIRA Solution Brochure

Removing barriers to patient care allows you to focus more on your patients. Learn more about the ULSPIRA Solution.

Click to learn more about the ULSPIRA solution

ULSPIRA Care+™

Put the + in your care. ULSPIRA Care+ is a human solution to remove even more of your burden of care when delivering nitric oxide therapy to patients.

• Always there. 24/7/365 access to Clinical Application Specialists (RRT).

• Customized, on–site support. Utilizing Airgas Therapeutics human resources to perform routine tasks, easing the burden of care for Respiratory Therapists and allowing hospital staff to focus on patient care.

• Patient-centric, value-based business approach: Available per treatment business model, made possible by novel patient treatment insights.

ULSPIRA Care+ is our human solution utilizing Airgas resources to perform routine tasks, easing the burden of care for Respiratory Therapists.

Focus on Safety

Cylinder management and transport

Optimize RT Time

High calibrations performed for you at your request

Minimize Emergencies

Inventory and supply management

Always Ready

Device preventive maintenance management

Patient-centric Approach

Per patient treatment data collection and sharing

ULSPIRA Indication and Important Safety Information

ULSPIRA (nitric oxide) gas, for inhalation, is a vasodilator indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.

Contraindications

ULSPIRA is contraindicated in neonates dependent on right-to-left shunting of blood.

Warnings and Precautions

• Rebound: Abrupt discontinuation of ULSPIRA may lead to worsening oxygenation and increasing pulmonary artery pressure.
• Methemoglogin: Methemoglobin increases with the dose of ULSPIRA and is dose dependent. Following discontinuation or reduction of nitric oxide, methemoglobin levels can take up to 8 hours or more to return to baseline. If methemoglobin levels do not resolve with decrease in dose or discontinuation of ULSPIRA, additional therapy may be warranted to treat methemoglobinemia.
• Elevated Levels: Monitor for PaO₂, inspired nitrogen dioxide (NO₂), and methemoglobin during ULSPIRA administration.
• Heart Failure: In patients with pre-existing left ventricular dysfunction, ULSPIRA may increase pulmonary capillary wedge pressure, leading to pulmonary edema.
• Nitrogen dioxide may cause airway inflammation and damage to lung tissues.

Adverse Reactions

The most common adverse reaction of ULSPIRA is hypotension.

Drug Interactions

Nitric Oxide donor compounds may increase the risk of developing methemoglobinemia.

Use With Delivery System

ULSPIRA must be administered using a calibrated FDA-cleared Nitric Oxide Delivery System operated by trained personnel. Only validated ventilator systems should be used in conjunction with ULSPIRA.

Adverse Events

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see full ULSPIRA prescribing information for additional ULSPIRA safety and risk information.

ULSPIRA TS Safety Statement

Intended Use

The ULSPIRA TS Nitric Oxide Therapy System is intended for use by healthcare professionals for the delivery of nitric oxide (NO) and the monitoring of inspired NO, NO₂ and O₂ concentrations for a patient undergoing inhaled Nitric Oxide (iNO) therapy.

ULSPIRA TS must only be used in accordance with the indications, contraindications, warnings and precautions described in the nitric oxide drug packaging inserts and labeling, and is indicated for use in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension. The primary targeted clinical setting is the Neonatal Intensive Care Unit (NICU) and secondary targeted clinical setting is the transport of neonates. Refer to this material prior to use.

In the case of an abrupt stop of inhaled NO gas delivery, withdrawal (rebound pulmonary hypertension) may occur. Possible side-effects of the inhaled NO gas therapy are further described in the nitric oxide drug packaging inserts and labeling.

ULSPIRA TS can be used with respiratory devices. Make sure that ULSPIRA TS is validated with the respiratory device you use. Validated respiratory devices are listed in the User's Manual.

Device Warnings:

• Persons using ULSPIRA TS must be trained and experienced in its use to ensure effective administration of nitric oxide and to avoid injury to the patient or to others resulting from inhalation of excess NO, NO₂ or other reaction products.
• Always perform a Pre-Use Check before connecting ULSPIRA TS to the patient. Only use the system if the Pre-Use Check is successfully passed.
• If an unintended treatment interruption occurs, use the backup system.
• ULSPIRA TS must not be used in an MRI environment.

Rx Only